Languages

Top Navigation (EN)

Introduction

The technologies that Soricimed is developing arise from the abilities of our peptides to modulate ion channel activity. The oncology management platform arises from the ability of soricidin and the C-series peptides to modulate the activity of a non-voltage gated calcium ion channel. The pain management technology arises from the ability of soricidin and the N-series peptides to inhibit voltage-gated sodium channels. While both functionalities lie in the structure of the parent peptide (soricidin) we have separated the two functional domains to provide two applications with no overlap in physiological action.